Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renzo Mignani

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|December 15, 2025
Prognostic role of myocardial storage, hypertrophy and inflammation/fibrosis in Fabry Cardiomyopathy: a new predictive score including T1 valuesAntonia Camporeale, Gianluigi Guida, Maurizio Pieroni, et al.
Journal of Medical Genetics|January 20, 2023
Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA studyAntonia Camporeale, Francesco Bandera, Maurizio Pieroni, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Parapelvic cysts, a distinguishing feature of renal Fabry diseaseAntonio Pisani, Luigi Petruzzelli Annicchiarico, Angela Pellegrino, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 7, 2007
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in ItalyRenzo Mignani, Sandro Feriozzi, Antonio Pisani, et al.
International Journal of Cardiology|November 7, 2025
Impact of cardiac magnetic resonance on the clinical management of patients with Fabry disease: Data from the CMR Italian research and CLinical nEtwork for Fabry disease (CIRCLE-FD)Antonia Camporeale, Giada De Angeli, Gianluigi Guida, et al.
Molecular Genetics and Metabolism|July 19, 2018
European expert consensus statement on therapeutic goals in Fabry diseaseChristoph Wanner, Michael Arad, Ralf Baron, et al.
International Journal of Cardiology|March 31, 2025
Electrocardiogram evolution in Anderson-Fabry disease patients during follow-up in relation to specific treatment and cardiac disease progressionVanda Parisi, Raffaello Ditaranto, Nevio Taglieri, et al.
International Journal of Molecular Sciences|November 28, 2018
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?Giovanni Duro, Carmela Zizzo, Giuseppe Cammarata, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Molecular Genetics and Metabolism Reports|February 19, 2019
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of expertsDominique P Germain, Perry M Elliott, Bruno Falissard, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|December 15, 2025
Prognostic role of myocardial storage, hypertrophy and inflammation/fibrosis in Fabry Cardiomyopathy: a new predictive score including T1 valuesAntonia Camporeale, Gianluigi Guida, Maurizio Pieroni, et al.
Journal of Medical Genetics|January 20, 2023
Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA studyAntonia Camporeale, Francesco Bandera, Maurizio Pieroni, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Parapelvic cysts, a distinguishing feature of renal Fabry diseaseAntonio Pisani, Luigi Petruzzelli Annicchiarico, Angela Pellegrino, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 7, 2007
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in ItalyRenzo Mignani, Sandro Feriozzi, Antonio Pisani, et al.
International Journal of Cardiology|November 7, 2025
Impact of cardiac magnetic resonance on the clinical management of patients with Fabry disease: Data from the CMR Italian research and CLinical nEtwork for Fabry disease (CIRCLE-FD)Antonia Camporeale, Giada De Angeli, Gianluigi Guida, et al.
Molecular Genetics and Metabolism|July 19, 2018
European expert consensus statement on therapeutic goals in Fabry diseaseChristoph Wanner, Michael Arad, Ralf Baron, et al.
International Journal of Cardiology|March 31, 2025
Electrocardiogram evolution in Anderson-Fabry disease patients during follow-up in relation to specific treatment and cardiac disease progressionVanda Parisi, Raffaello Ditaranto, Nevio Taglieri, et al.
International Journal of Molecular Sciences|November 28, 2018
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?Giovanni Duro, Carmela Zizzo, Giuseppe Cammarata, et al.
Pageof 7